论文部分内容阅读
目的 :研究蕲蛇酶治疗急性脑梗塞的临床疗效及不良反应。方法 :将 117例急性脑梗塞患者随机分成治疗组 (A组 ) 6 5例 ,对照组 (B组 ) 5 2例。两组分别予蕲蛇酶 (0 .75U)和生理盐水 1ml,溶于 2 5 0ml生理盐水中静滴 ,然后用维脑路通 15 0mg溶于 5 0 0ml 5 %葡萄糖溶液中静滴 ,qd ,7d为一疗程。结果 :A组显效率为 6 9.2 % ,较B组 44 .2 %明显升高 (P <0 .0 1) ;治疗后凝血指标显著下降 (P <0 .0 5 ) ;颅脑CT复查低密度灶平均体积显著小于B组 (P <0 .0 1)。结论 :蕲蛇酶是一种新型的降纤抗栓、改善微循环的药物。
Objective: To study the clinical efficacy and adverse reactions of Acutobin in the treatment of acute cerebral infarction. Methods: 117 patients with acute cerebral infarction were randomly divided into treatment group (A group) 65 cases, control group (B group) 52 cases. Two groups were given snake venom enzyme (0.75U) and saline 1ml, dissolved in 250ml normal saline intravenous drip, and then with Victoria brain pass 150mg dissolved in 500ml of 5% glucose solution, intravenous infusion, qd , 7d for a course of treatment. Results: The effective rate in group A was 62.2%, which was significantly higher than that in group B 44.2% (P <0.01). The coagulation index decreased significantly after treatment (P <0.05) The average volume of density lesions was significantly less than that of group B (P <0.01). Conclusion: Acutobin is a new type of anti-fibrinolysis and anti-microcirculation drugs.